in accordance with sfas no . 142 , goodwill and other intangible assets , the goodwill is not amortized , but will be subject to a periodic assessment for impairment by applying a fair-value-based test . none of this goodwill is expected to be deductible for tax purposes . the company performs its annual test for impairment of goodwill in may of each year . the company is required to perform a periodic assessment between annual tests in certain circumstances . the company has performed its annual test of goodwill as of may 1 , 2006 and has determined there was no impairment of goodwill during 2006 . the company allocated $ 15.8 million of the purchase price to in-process research and development projects . in-process research and development ( ipr&d ) represents the valuation of acquired , to-be- completed research projects . at the acquisition date , cyvera 2019s ongoing research and development initiatives were primarily involved with the development of its veracode technology and the beadxpress reader . these two projects were approximately 50% ( 50 % ) and 25% ( 25 % ) complete at the date of acquisition , respectively . as of december 31 , 2006 , these two projects were approximately 90% ( 90 % ) and 80% ( 80 % ) complete , respectively . the value assigned to purchased ipr&d was determined by estimating the costs to develop the acquired technology into commercially viable products , estimating the resulting net cash flows from the projects , and discounting the net cash flows to their present value . the revenue projections used to value the ipr&d were , in some cases , reduced based on the probability of developing a new technology , and considered the relevant market sizes and growth factors , expected trends in technology , and the nature and expected timing of new product introductions by the company and its competitors . the resulting net cash flows from such projects are based on the company 2019s estimates of cost of sales , operating expenses , and income taxes from such projects . the rates utilized to discount the net cash flows to their present value were based on estimated cost of capital calculations . due to the nature of the forecast and the risks associated with the projected growth and profitability of the developmental projects , discount rates of 30% ( 30 % ) were considered appropriate for the ipr&d . the company believes that these discount rates were commensurate with the projects 2019stage of development and the uncertainties in the economic estimates described above . if these projects are not successfully developed , the sales and profitability of the combined company may be adversely affected in future periods . the company believes that the foregoing assumptions used in the ipr&d analysis were reasonable at the time of the acquisition . no assurance can be given , however , that the underlying assumptions used to estimate expected project sales , development costs or profitability , or the events associated with such projects , will transpire as estimated . at the date of acquisition , the development of these projects had not yet reached technological feasibility , and the research and development in progress had no alternative future uses . accordingly , these costs were charged to expense in the second quarter of 2005 . the following unaudited pro forma information shows the results of the company 2019s operations for the years ended january 1 , 2006 and january 2 , 2005 as though the acquisition had occurred as of the beginning of the periods presented ( in thousands , except per share data ) : year ended january 1 , year ended january 2 .

Table: year ended january 1 2006 year ended january 2 2005 revenue $ 73501 $ 50583 net loss -6234 ( 6234 ) -9965 ( 9965 ) net loss per share basic and diluted -0.15 ( 0.15 ) -0.27 ( 0.27 )

illumina , inc . notes to consolidated financial statements 2014 ( continued ) .

Question: what was the percentage change in revenues between 2005 and 2006?
Answer: 45%
Calculation: divide(subtract(73501, 50583), 50583)